SAN

85.82

-0.54%↓

MRK1

115.55

0%↓

ARGX

791.2

-0.73%↓

PHIA

24.28

+0.08%↑

ONC.US

340.64

+1.61%↑

SAN

85.82

-0.54%↓

MRK1

115.55

0%↓

ARGX

791.2

-0.73%↓

PHIA

24.28

+0.08%↑

ONC.US

340.64

+1.61%↑

SAN

85.82

-0.54%↓

MRK1

115.55

0%↓

ARGX

791.2

-0.73%↓

PHIA

24.28

+0.08%↑

ONC.US

340.64

+1.61%↑

SAN

85.82

-0.54%↓

MRK1

115.55

0%↓

ARGX

791.2

-0.73%↓

PHIA

24.28

+0.08%↑

ONC.US

340.64

+1.61%↑

SAN

85.82

-0.54%↓

MRK1

115.55

0%↓

ARGX

791.2

-0.73%↓

PHIA

24.28

+0.08%↑

ONC.US

340.64

+1.61%↑

Search

Laboratorios Farmaceuticos Rovi SA

Închisă

SectorSănătate

58.75 -0.34

Rezumat

Modificarea prețului

24h

Curent

Minim

58.55

Maxim

59.1

Indicatori cheie

By Trading Economics

Venit

31M

58M

Vânzări

51M

210M

P/E

Medie Sector

24.852

79.874

EPS

1.135

Randament dividend

1.61

Marjă de profit

27.571

Angajați

2,197

EBITDA

4.2M

35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+53.32% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.61%

2.31%

Statistici piață

By TradingEconomics

Capitalizare de piață

-235M

3B

Deschiderea anterioară

59.09

Închiderea anterioară

58.75

Sentimentul știrilor

By Acuity

50%

50%

168 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 nov. 2025, 16:49 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov. 2025, 15:32 UTC

Achiziții, Fuziuni, Preluări

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov. 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov. 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 nov. 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov. 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov. 2025, 15:54 UTC

Achiziții, Fuziuni, Preluări

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov. 2025, 15:44 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov. 2025, 15:43 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov. 2025, 15:42 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov. 2025, 15:41 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov. 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov. 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov. 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov. 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 nov. 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov. 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov. 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27 nov. 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov. 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov. 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27 nov. 2025, 11:07 UTC

Câștiguri

Genting: Positive About Prospects Over Longer Term

27 nov. 2025, 11:06 UTC

Câștiguri

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov. 2025, 11:04 UTC

Câștiguri

Genting: International Travel Demand Expected to Remain Resilient

27 nov. 2025, 11:04 UTC

Câștiguri

Genting: Global Growth Expected to Remain Subdued

27 nov. 2025, 11:04 UTC

Câștiguri

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov. 2025, 10:59 UTC

Câștiguri

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov. 2025, 10:58 UTC

Câștiguri

Genting Bhd 3Q Rev Rose 14% on Year

27 nov. 2025, 10:56 UTC

Câștiguri

Genting Bhd 3Q Net MYR30.3M

27 nov. 2025, 10:56 UTC

Câștiguri

Genting Bhd 3Q EPS MYR0.0079

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

53.32% sus

Prognoză pe 12 luni

Medie 90 EUR  53.32%

Maxim 90 EUR

Minim 90 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

168 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat